Novavax’s Revenue Falls Short. Management Expects a Surge.


The Covid-19 vaccine maker Novavax expects sales of between $4 billion and $5 billion in 2022, it said Monday as it reported less revenue than expected for the fourth quarter.

The biotech reported revenues of $222 million after the market closed. The consensus call among analysts surveyed by FactSet was for $332 million.

Novavax’s Covid-19…

As Russian Market Goes Dark, U.S. ETFs Show Extent of Damage

Previous article

Dow Jones Falls As Ukraine Fighting Rages On; 3 Defense Stocks Pass Buy Points; Tesla Surges After This

Next article

You may also like


Leave a reply

Your email address will not be published.

More in News